Trinity Biotech plc
NASDAQ:TRIBMedical - Diagnostics & Research
-$0.51 today
- Market cap
- $117.96M
- Beta
- 1.00
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$60.27
Volume 0.00M
Average 1.34M
TRIB Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Trinity Biotech plcNASDAQ: TRIB
Retained Earnings · Q4 FY2025 · quarter ended Dec 2025
Retained earnings remains negative
Q4 FY2025 retained earnings was -$116.17M, compared with -$79.12M a year earlier.
Context
- Retained earnings amounted to 110.5% of total assets at the end of Q4 FY2025, up 33.9 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -46.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (116.17M) USD
- Year-over-year change
- -46.8%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (116.17M) | -46.8% |
| FY2024 | 2024-12-31 | (79.12M) | -62.6% |
| FY2023 | 2023-12-31 | (48.64M) | -82.2% |
| FY2022 | 2022-12-31 | (26.7M) | -312.6% |
| FY2021 | 2021-12-31 | 12.56M | — |
Retained Earnings vs competitors
How TRIB compares with its peers on the latest reported figures
No competitor Retained Earnings figures are available to compare.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 25.91M | 6.58M | 3.69M | 5.17M | 5.14M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 15.71M | 15.65M | 13.38M | 14.6M | 10.28M |
| Inventory | 29.12M | 22.5M | 19.93M | 19.37M | 18.83M |
| Other Current Assets | 0 | 1K | 0 | 0 | 0 |
| Total Current Assets | 72.69M | 46.67M | 39.04M | 41.12M | 35.9M |
| Property, Plant & Equipment (Net) | 5.92M | 5.68M | 1.89M | 4.62M | 5.3M |
| Goodwill | 12.54M | 12.54M | 0 | 13.84M | 13.97M |
| Intangible Assets | 23.44M | 22.73M | 16.27M | 37.5M | 43.02M |
| Long-term Investments | 151K | 212K | 214K | 2.46M | 3.02M |
| Tax Assets | 4.1M | 4.22M | 1.98M | 3.55M | 3.92M |
| Other Non-current Assets | 56K | 55K | 43K | 194K | 28K |
| Total Non-current Assets | 46.21M | 45.44M | 20.39M | 62.17M | 69.26M |
| Total Assets | 118.9M | 92.1M | 59.44M | 103.29M | 105.17M |
| Account Payables | 6.76M | 6.21M | 3.89M | 6.83M | 11.48M |
| Short-term Debt | 83.31M | 210K | 210K | 210K | 110.81M |
| Tax Payables | 420K | 28K | 279K | 1.02M | 0 |
| Deferred Revenue | 141K | 114K | 50K | 197K | 187K |
| Other Current Liabilities | 249K | 153K | 160K | 2.57M | 18.38M |
| Total Current Liabilities | 100.49M | 17.34M | 15.04M | 32.1M | 141.21M |
| Long-term Debt | 0 | 58.05M | 54.65M | 87.79M | 16.33M |
| Deferred Tax Liabilities | 4.86M | 5.06M | 2.3M | 4.56M | 4.67M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 4.86M | 1.57M | 526K | 3.55M | 4.1M |
| Total Non-current Liabilities | 18.72M | 76.94M | 68.35M | 106.38M | 35.94M |
| Total Liabilities | 119.21M | 94.28M | 83.38M | 138.47M | 177.15M |
| Common Stock | 1.21M | 1.96M | 1.97M | 4.19M | 40K |
| Retained Earnings | 12.56M | (26.7M) | (48.64M) | (79.12M) | (116.17M) |
| Accumulated OCI | (5.36M) | (5.69M) | 1.03M | (5.44M) | 5.27M |
| Other Stockholders Equity | 0 | 6.71M | 0 | 6.71M | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (319K) | (2.18M) | (23.95M) | (35.18M) | (71.98M) |
| Total Debt | 99.16M | 72.2M | 67.43M | 100.76M | 137.98M |
| Net Debt | 73.25M | 51.68M | 63.74M | 95.6M | 132.85M |
Trinity Biotech plc
NASDAQ:TRIB
Intrinsic Alpha fair value
Locked
Current Price
$5.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.